Moreover, our group and others have demonstrated that the spliceosome, the cellular machinery controlling the splicing process, is drastically altered in GBM and different cancer types [7, 23, 31, 34, 67], leading to the appearance of aberrant/oncogenic splicing variants (SVs) from different genes [e.g., GFAP [47]/VEGF [26]/TP53 [2]/BCL2L1 [72]/TP73 [23]]. This evidence concerns the gene BCL2L1 and glioblastoma.